The DOI matches its Crossref record.
PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION
Abstract
PURPOSE: Intravitreal injections can cause several ocular complications, including vitreous hemorrhage, endophthalmitis, retinal detachment, and cataract, and clearly repeated injections can multiply the risk of these complications. Bevacizumab is used for the treatment of different ocular diseases. For improvement of drug availability after intravitreal administration, in this study, liposomal bevacizumab as a novel drug delivery system was prepared and compared with conventional formulas in the market. METHODS: Bevacizumab was encapsulated into liposomes via the dehydration-rehydration method. After reducing the size of liposome to the nanoscale, the final liposomal formulation was tested in an animal model. Left eyes of rabbits received liposomal bevacizumab and the right eyes were injected by soluble bevacizumab. The free drug concentration in aqueous humor and vitreous samples at Days 3, 7, 14, 28, and 42 after the injection was determined by enzyme-linked immunosorbent assay. RESULTS: Mean concentration of free bevacizumab in the eyes that received liposomal bevacizumab compared with the eyes injected with soluble bevacizumab was 1 (48 versus 28 microg/mL) and 5 (16 versus 3.3 microg/mL) times higher at Days 28 and 42, respectively. Mean concentration of free bevacizumab in the aqueous humor of both injected eyes was almost the same at the different intervals. CONCLUSION: The results of this study showed the beneficial effects of liposomes in prolonging the residency of bevacizumab in the vitreous.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ocular drug delivery systems: An overview
Patel, A. (2013) · World Journal of Pharmacology · doi:10.5497/wjp.v2.i2.47 · Cited by 890
Sustained-release from nanocarriers: a review
Natarajan, J. V., Nugraha, C., Ng, X. W., & Venkatraman, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.029 · Cited by 285
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Nanotherapy for posterior eye diseases
Kaur, I. P., & Kakkar, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.031 · Cited by 175
Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s383101 · Cited by 111
Metadata
- Authors
- ABRISHAMI, M., GANAVATI, S. Z., SOROUSH, D., ROUHBAKHSH, M., JAAFARI, M. R., & MALAEKEH-NIKOUEI, B.
- Venue
- Retina
- Published
- 2009-05
- Volume
- 29
- Issue
- 5
- Pages
- 699-703
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2044125840
- Cited by
- 184
- References
- 0
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION. https://app.cochat.ai/papers/10.1097/iae.0b013e3181a2f42a
- The paper
- ABRISHAMI, M., GANAVATI, S. Z., SOROUSH, D., ROUHBAKHSH, M., JAAFARI, M. R., & MALAEKEH-NIKOUEI, B. (2009). PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION. Retina. https://doi.org/10.1097/iae.0b013e3181a2f42a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.